You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com

 Google Custom Search
Zerit (d4T, stavudine)

Articles on Zerit
Full US Prescribing Information

Zerit is in a category of HIV medications called nucleoside reverse transcriptase inhibitors (NRTIs).

Zerit, manufactured by Bristol-Myers Squibb, was approved by the U.S. Food and Drug Administration for the treatment of HIV in 1994.


Articles on Zerit


FDA Updates Label Information for Stavudine (Zerit)
12-13-2010

Benefits versus Risks of Stavudine (Zerit) Therapy for HIV-related Neurological Complications
2-03-2009

Longer Exposure to NRTIs, especially Stavudine (Zerit), Increases the Risk of Insulin Resistance in Women with HIV
1-30-2009


Long-term Fat Loss among Treatment-naive Patients Starting Combination Therapy Containing Stavudine (Zerit), Zidovudine (Retrovir), or Abacavir (Ziagen)
5-03-2008

What Is the Impact on Lipoatrophy and Dyslipidemia of Reducing the Dose of d4T (Zerit) Compared with Switching to Tenofovir (Viread)?
1-15-2008